LIVE ORAL SHIGELLA DYSENTERIAE VACCINE

Technology Summary

*Shigella* cause millions of cases of dysentery every year, which result in 700,000 deaths worldwide. *Shigella dysenteriae* serotype 1, one of about forty serotypes of *Shigella*, causes a more severe disease with a much higher mortality rate than other serotypes. There are no licensed vaccines available for protection against *Shigella*. The fact that many isolates exhibit multiple antibiotic resistance complicates the management of dysentery infections.

FDA Researchers developed a *Salmonella* typhi Ty21a construct comprising a *Shigella dysenteriae* O-specific polysaccharide (O-Ps) inserted into the *Salmonella* typhi Ty21a chromosome, where heterologous *Shigella dysenteriae* serotype 1 O-antigen is stably expressed together with homologous *Salmonella typhi* O-antigen. The constructs elicit immune protection against virulent *Shigella dysenteriae* challenge, as well as *Salmonella typhi* challenge. The construct can be used as a new vaccine candidate, stable for vaccine manufacture, and provides combined protection against enteric fevers due to *Salmonella typhi* and *Salmonella sonnei*.

Potential Commercial Applications

- One component of a multivalent anti-shigellosis vaccine under development
- Shigella vaccines, therapeutics and diagnostics

Competitive Advantages

- Oral vaccine - no needles required
- Lower cost of production
- Low cost vaccine
- Temperature-stable manufacturing process - avoids need for refrigeration during vaccine distribution

Development Stage: *in vivo*, mouse challenge studies

Inventors: Dennis Kopecko, De Qi Xu

Publications:

“Core-linked LPS expression of Shigella dysenteriae serotype 1 O-antigen in live Salmonella Typhi vaccine vector Ty21a: preclinical evidence of immunogenicity and protection.” *Vaccine* 2007 Aug;25(33):6167-75
PMID: [17629369](https://www.ncbi.nlm.nih.gov/pubmed/17629369)

Intellectual Property:

- United States Patent: [8,071,113](https://patft.uspto.gov/netacq/patft/ShowProduct.jsp?RefType=ShowAll&RefNum=8071113), issued 12.06.2011
- United States Patent: [8,790,635](https://patft.uspto.gov/netacq/patft/ShowProduct.jsp?RefType=ShowAll&RefNum=8790635), issued 07.29.2014
- United States Patent: [8,968,719](https://patft.uspto.gov/netacq/patft/ShowProduct.jsp?RefType=ShowAll&RefNum=8968719), issued 03.03.2015
- European Patents: 1756149, issued 09.04.2013

Product Area: Biologics, Vaccines

FDA Reference No: E-2004-022

Licensing Contact:

Ken Millburne, J.D.
FDA Technology Transfer Program
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 240-402-4315